March 29, 2017
The Rosen Law Firm did not engage in "abusive litigation" when filing a shareholder suit that alleged Cellceutix Corp. had hyped two of its drugs to inflate stock prices, a New York federal judge ruled Wednesday, refusing to sanction the firm for soliciting investors just hours after a report attacked Cellceutix's business.
June 08, 2016
A New York federal judge on Wednesday freed Cellceutix Corp. from a proposed shareholder class action alleging that the biotechnology company fraudulently hyped two of its drugs to inflate stock prices, saying the suit failed to show any dishonest statements by Cellceutix.
September 11, 2015
A proposed securities class action filed Friday in New York federal court accuses biotechnology company Cellceutix Corp. of fraudulently hyping two of its drugs to inflate stock prices, leading to a precipitous drop when an online report accused the company of being a shell corporation.